A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports. Image: The new drug candidate, shown in green, fits precisely into the active site within the target protein, retonoid X receptor. Credit: Dipanjan Pan, University...
Tag: <span>MELANOMA</span>
Post
AAD releases new guidelines for the tx of cutaneous melanoma
Susan M. Swetter, M.D., from Stanford University Medical Center in California, and colleagues reviewed the evidence and made treatment recommendations for patients with primary cutaneous melanoma. New guidelines have been released for the treatment of primary cutaneous melanoma, according to a report from the American Academy of Dermatology published online Nov. 1 in the Journal of...
Post
Team studying rare disorder discovers novel way to target melanoma
While studying a rare genetic disorder called NGLY1 deficiency, University of North Texas Health Science Center (UNTHSC) researchers discovered a new targeted treatment for combating melanoma, a skin cancer that kills about 9,000 people in the United States each year. IMAGE: THIS IS YU-CHIEH WANG, PH.D., AND VICTOR LIN, MS, UNT SYSTEM COLLEGE OF PHARMACY, UNT...
Post
Melanoma: More evidence that antioxidants speed up tumor spread
New research evidence backs up previous findings that taking antioxidant supplements can speed up the spread of the deadliest form of skin cancer. close up of a mole Antioxidants either have no effect or hasten the spread of melanoma tumors, according to a new study. Researchers at the University of Gothenburg in Sweden have added...
Post
Specific CD8 T cell states may indicate response to immune checkpoint therapy for melanoma
A multi-institutional research team, led by investigators at Massachusetts General Hospital (MGH) and the Broad Institute of MIT and Harvard, has identified specific states of cytotoxic CD8 T cells that are associated with patient response to checkpoint immunotherapy for melanoma. Their report published in the journal Cell also identifies specific marker proteins associated with these...
Post
Melanoma Patient Response to Immune Checkpoint Inhibitors Predicted by Expression-Based Score
NEW YORK (GenomeWeb) – A team led by researchers at the University of Maryland and the National Cancer Institute has developed a gene expression-based predictor of response to immune checkpoint blockade therapy in metastatic melanoma patients. In a study published yesterday in Nature Medicine, the scientists, led by senior author Eytan Ruppin and first author Noam Auslander,...
Post
Scientists identify weak point in deadly eye melanoma
Plant compound shuts down tumor growth WASHINGTON UNIVERSITY SCHOOL OF MEDICINE A natural plant compound exploits a newly identified Achilles’ heel in a cancer of the eye, uveal melanoma. In human cancer cells growing in the lab, the compound shuts down the overactive signaling that drives uveal melanoma cell growth, according to researchers at Washington University School...
Post
Combination approach shows promise for beating advanced melanoma
In UCLA-led study, new treatment is more effective in people receiving immunotherapy for the first time UNIVERSITY OF CALIFORNIA – LOS ANGELES HEALTH SCIENCES A UCLA-led study has found that a treatment that uses a bacteria-like agent in combination with an immunotherapy drug could help some people with advanced melanoma, an aggressive form of skin...
Post
Research team develops predictor for immunotherapy response in melanoma
In a new study, researchers developed a gene expression predictor that can indicate whether melanoma in a specific patient is likely to respond to treatment with immune checkpoint inhibitors, a novel type of immunotherapy. The predictor was developed by Noam Auslander, Ph.D., with other researchers in the Center for Cancer Research (CCR) at the National Cancer Institute (NCI), part of the...
Post
Combination immunotherapy shrinks melanoma brain metastases
Combination immunotherapy shrank melanoma that has spread to the brain in more than half of the patients in a clinical trial reported in the New England Journal of Medicine led by an investigator at The University of Texas MD Anderson Cancer Center. Hussein Tawbi, M.D., Ph.D. Credit: MD Anderson Cancer Center Of 94 patients in the single-arm study combining...